Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma |
| |
| Affiliation: | 1. Department of Rheumatology and Imunology, Peking University ShenZhen Hospital, Shenzhen, China;2. Clinical College of Peking University Shenzhen Hospital of Anhui Medical University, Anhui, China;3. Department of Center Lab, Peking University ShenZhen Hospital, Shenzhen, China;1. Division of Hematology, University Hospital and University of Zurich, Zurich, Switzerland;2. Institute of Primary Care, University Hospital and University of Zurich, Zurich, Switzerland;3. Department of Internal Medicine, Kantonsspital Munsterlingen, Munsterlingen, Switzerland;1. The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, China;2. Guangxi Medical University, Nanning 530021, China;3. Department of Biochemistry, University of Arkansas Medical School, 4301W. Markham, Little Rock, AR 72205-7199, USA;1. Hematology and Bone Marrow Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy;2. Hematology, Ospedale Di Miccoli, Barletta, Italy;3. Hematology, Ospedale Vito Fazzi, Lecce, Italy;4. Hematology, Ospedale Cardinale Panico, Tricase, LE, Italy;5. Hematology, Ospedale San Giuseppe Moscati, Taranto, Italy;6. Hematology, Ospedale Perrino, Brindisi, Italy;7. Hematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy;8. Hematology, Istituto Tumori Giovanni Paolo II, Bari, Italy;9. Hematology, Ospedali Riuniti, Foggia, Italy;1. Shandong Jining NO.1 People’s Hospital, Jining, PR China;2. Jining Medical University, Jining, PR China |
| |
| Abstract: | Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphomas. Exploring a novel and important biomarker is indispensable for understanding the mechanism and clinical course of DLBCL. Emerging studies have shown that aberrant expression of long noncoding RNA (lncRNAs) is strongly associated with carcinogenesis. The aim of this study was to investigate the value of lncRNA LUNAR1 in DLBCL. Quantitative real-time PCR was performed to illustrate the patterns of LUNAR1 expression in tumor tissues and cell lines. The higher expression of LUNAR1 was significantly correlated with stage, rituximab and IPI. Univariate and multivariate analyses showed that LUNAR1 expression served as an independent predictor for overall survival and progression-free survival. Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values and the area under the ROC curve of LUNAR1 was up to 0.9420. Further experiments revealed that LUNAR1 knockdown significantly repressed cell proliferation of DLBCL by regulating E2F1, cyclin D1 and p21. In conclusion, our results indicate that LUNAR1 may serve as a candidate prognostic biomarker through growth regulation in DLBCL. |
| |
| Keywords: | LUNAR1 Long noncoding RNAs Prognosis Biomarker DLBCL |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
